LTFS
ALXN

Ladenburg Thalmann Financial Services’s Alexion Pharmaceuticals ALXN Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$706K Buy
6,756
+3,612
+115% +$386K ﹤0.01% 1540
2019
Q3 		$308K Sell
3,144
-957
-23% -$108K ﹤0.01% 2153
2019
Q2 		$538K Buy
4,101
+184
+5% +$23.7K ﹤0.01% 1688
2019
Q1 		$531K Buy
3,917
+218
+6% +$27.1K ﹤0.01% 1646
2018
Q4 		$360K Buy
3,699
+524
+17% +$61.9K ﹤0.01% 1785
2018
Q3 		$441K Sell
3,175
-679
-18% -$85.2K ﹤0.01% 1707
2018
Q2 		$429K Hold
3,854
– – ﹤0.01% 1665
2018
Q1 		$429K Buy
3,854
+338
+10% +$40.4K ﹤0.01% 1665
2017
Q4 		$422K Sell
3,516
-414
-11% -$50.4K ﹤0.01% 1666
2017
Q3 		$552K Buy
3,930
+294
+8% +$39.9K 0.01% 1397
2017
Q2 		$441K Buy
3,636
+1,331
+58% +$155K 0.01% 1465
2017
Q1 		$279K Buy
2,305
+272
+13% +$35.1K ﹤0.01% 1684
2016
Q4 		$275K Buy
2,033
+209
+11% +$25.6K ﹤0.01% 1614
2016
Q3 		$227K Buy
1,824
+436
+31% +$56.1K ﹤0.01% 1677
2016
Q2 		$161K Buy
1,388
+33
+2% +$4.68K ﹤0.01% 1815
2016
Q1 		$191K Sell
1,355
-394
-23% -$57.9K ﹤0.01% 1638
2015
Q4 		$330K Sell
1,749
-1,108
-39% -$194K 0.01% 1258
2015
Q3 		$448K Sell
2,857
-1,739
-38% -$317K 0.01% 1029
2015
Q2 		$819K Buy
4,596
+1,318
+40% +$227K 0.02% 816
2015
Q1 		$567K Buy
3,278
+60
+2% +$10.9K 0.01% 973
2014
Q4 		$592K Buy
3,218
+883
+38% +$164K 0.01% 837
2014
Q3 		$387K Sell
2,335
-128
-5% -$21K 0.01% 903
2014
Q2 		$385K Buy
2,463
+26
+1% +$4.11K 0.01% 882
2014
Q1 		$371K Sell
2,437
-3,435
-58% -$546K 0.01% 846
2013
Q4 		$780K Buy
5,872
+3,407
+138% +$409K 0.02% 536
2013
Q3 		$286K Sell
2,465
-131
-5% -$14.4K 0.01% 865
2013
Q2 		$243K Buy
+2,596
New +$250K 0.01% 897

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ladenburg Thalmann Financial Services's ALXN Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services increased its Alexion Pharmaceuticals (ALXN) stake by 115% in Q4 2019, buying an estimated $386K and bringing the position to 6,756 shares worth $706K. The position accounts for ﹤0.01% of the portfolio, ranked #1540.

Ladenburg Thalmann Financial Services first reported a position in ALXN in Q2 2013 and has held it in 27 quarters since. The position peaked at $819K in Q2 2015. 667 funds tracked by Wall St. Rank hold ALXN as of Q4 2019.

  • Ladenburg Thalmann Financial Services held 6,756 shares of Alexion Pharmaceuticals worth $706K as of Q4 2019.
  • Ladenburg Thalmann Financial Services bought 3,612 Alexion Pharmaceuticals shares in Q4 2019, an estimated $386K.
  • Alexion Pharmaceuticals made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #1540 holding.
  • Ladenburg Thalmann Financial Services first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 27 quarters since.
  • Ladenburg Thalmann Financial Services's Alexion Pharmaceuticals position peaked at $819K in Q2 2015.
  • 667 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.